Thus, in addition to identifying a targeted therapy that would never have been considered in this clinical setting, the gene expression analysis of our patient’s tumor contributed to our understanding of the biology of myoepithelial carcinoma and identified a potentially useful immunohistochemical marker for identifying future patients who might benefit from CDK4/6 inhibitors. Here, CDK4 is linked to malignant myoepithelioma.